- Home
- UDMY vs EWTX Comparison
UDMY vs EWTX Comparison
Compare UDMY & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UDMY
- EWTX
- Stock Information
- Founded
- UDMY 2009
- EWTX 2017
- Country
- UDMY United States
- EWTX United States
- Employees
- UDMY N/A
- EWTX N/A
- Industry
- UDMY Other Consumer Services
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- UDMY Real Estate
- EWTX Health Care
- Exchange
- UDMY Nasdaq
- EWTX Nasdaq
- Market Cap
- UDMY 1.1B
- EWTX 1.2B
- IPO Year
- UDMY 2021
- EWTX 2021
- Fundamental
- Price
- UDMY $6.94
- EWTX $14.30
- Analyst Decision
- UDMY Buy
- EWTX Buy
- Analyst Count
- UDMY 11
- EWTX 8
- Target Price
- UDMY $10.10
- EWTX $39.63
- AVG Volume (30 Days)
- UDMY 1.0M
- EWTX 932.9K
- Earning Date
- UDMY 07-30-2025
- EWTX 08-07-2025
- Dividend Yield
- UDMY N/A
- EWTX N/A
- EPS Growth
- UDMY N/A
- EWTX N/A
- EPS
- UDMY N/A
- EWTX N/A
- Revenue
- UDMY $790,019,000.00
- EWTX N/A
- Revenue This Year
- UDMY $1.87
- EWTX N/A
- Revenue Next Year
- UDMY $4.15
- EWTX N/A
- P/E Ratio
- UDMY N/A
- EWTX N/A
- Revenue Growth
- UDMY 5.43
- EWTX N/A
- 52 Week Low
- UDMY $5.68
- EWTX $10.60
- 52 Week High
- UDMY $10.61
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- UDMY 43.44
- EWTX 41.90
- Support Level
- UDMY $6.84
- EWTX $14.87
- Resistance Level
- UDMY $7.10
- EWTX $15.68
- Average True Range (ATR)
- UDMY 0.25
- EWTX 0.67
- MACD
- UDMY -0.08
- EWTX -0.02
- Stochastic Oscillator
- UDMY 11.11
- EWTX 15.25
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.